Depixus Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 62


  • Latest Deal Type
  • Series B
  • (Upcoming)

  • Investors
  • 7

Depixus General Information


Developer of a novel technology intended to offer real-time analysis of individual biomolecular interactions at a massive scale. The company's technology has wide-ranging applications and specializes in a full genomic region to be analyzed swiftly and easily on a single integrated platform with the investigator to specify the level of sequence and epigenetic detail required, thereby enabling researchers to reveal new biological pathways, decode disease mechanisms, and unlock routes to develop new precision medicines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Other Devices and Supplies
Corporate Office
  • 3-5 Impasse Reille
  • 75014 Paris
  • France
+33 09 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Depixus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) Upcoming Product Development
4. Later Stage VC (Series A) 02-Dec-2021 000.00 000.00 000.00 Completed Product Development
3. Grant 01-May-2019 00.000 00.00 Completed Product Development
2. Seed Round 06-Jun-2016 $7.2M $7.2M Completed Startup
1. Accelerator/Incubator 26-Nov-2013 Completed Startup
To view Depixus’s complete valuation and funding history, request access »

Depixus Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00 00 00 00 00.000
To view Depixus’s complete cap table history, request access »

Depixus Comparisons

HQ Location
Total Raised
Post Valuation
Developer of a novel technology intended to offer real-time analysis of individual biomolecular interactions at a massiv
Drug Discovery
Paris, France
62 As of 2024
000000 0


cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pr
0000000000 000000000
Munich, Germany
00 As of 0000
000000 0 000.00


it, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim a
Amsterdam, Netherlands
000 As of 0000
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Depixus Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynamic Biosensors Venture Capital-Backed Munich, Germany 00 000.00 000000 0 000.00
LUMICKS Venture Capital-Backed Amsterdam, Netherlands 000 000.00 00000000000 000.00
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom 0000 00.000 000000000 00.000
Roswell Biotechnologies Venture Capital-Backed San Diego, CA 00 0000 00000 00000
Carterra Venture Capital-Backed Salt Lake City, UT 00 000.00 000000000 00 000.00
You’re viewing 5 of 22 competitors. Get the full list »

Depixus Patents

Depixus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230375542-A1 Methods of screening compounds Pending 01-Apr-2022 000000000000
EP-4160199-A1 Apparatus for biomolecule analysis with a well and a cavity below the well Pending 04-Oct-2021 00000000000 00
EP-3914949-A1 Multichannel close-up imaging device Pending 24-Jan-2019 0000000000
US-20220091401-A1 Multichannel close-up imaging device Active 24-Jan-2019 0000000000 00
EP-3686642-A1 Multichannel close-up imaging device Inactive 24-Jan-2019 G02B17/084 00
To view Depixus’s complete patent history, request access »

Depixus Executive Team (8)

Name Title Board Seat Contact Info
Gordon Hamilton Ph.D Co-Founder, Chief Executive Officer & Board Member
Fabien Guillemot Finance Director
Steve Klose Chief Commercial Officer
Stephen Allen Ph.D Chief Business Officer & Board Member
David Bensimon Ph.D Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Depixus Board Members (10)

Name Representing Role Since
Gordon Hamilton Ph.D Depixus Co-Founder, Chief Executive Officer & Board Member 000 0000
John Berriman Self Chairman 000 0000
Lachlan MacKinnon Lansdowne Partners Board Member 000 0000
Mark Chin Arix Bioscience Board Observer 000 0000
Ronald Lindsay Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Depixus Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Depixus Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Casdin Capital Venture Capital Minority 000 0000 000000 0
Lansdowne Partners Hedge Fund Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Innovate UK Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Depixus FAQs

  • When was Depixus founded?

    Depixus was founded in 2012.

  • Who is the founder of Depixus?

    Gordon Hamilton Ph.D, Chas André Ph.D, David Bensimon Ph.D, and Vincent Croquette are the founders of Depixus.

  • Who is the CEO of Depixus?

    Gordon Hamilton Ph.D is the CEO of Depixus.

  • Where is Depixus headquartered?

    Depixus is headquartered in Paris, France.

  • What is the size of Depixus?

    Depixus has 62 total employees.

  • What industry is Depixus in?

    Depixus’s primary industry is Drug Discovery.

  • Is Depixus a private or public company?

    Depixus is a Private company.

  • What is Depixus’s current revenue?

    The current revenue for Depixus is 00000.

  • How much funding has Depixus raised over time?

    Depixus has raised $42.1M.

  • Who are Depixus’s investors?

    Bpifrance, Casdin Capital, Lansdowne Partners, Horizon 2020 SME Instrument, and Innovate UK are 5 of 7 investors who have invested in Depixus.

  • Who are Depixus’s competitors?

    Dynamic Biosensors, LUMICKS, Oxford Nanopore Technologies, Roswell Biotechnologies, and Carterra are some of the 22 competitors of Depixus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »